This clinical trial focuses on studying treatments for colon cancer, specifically in patients with operable Stage III and high-risk Stage II colon cancer. The trial aims to explore a personalized treatment approach based on blood and tumor characteristics to guide the post-surgical clinical path of these patients. The study will use a variety of medications, including Disodium Levofolinate, Temozolomide, Irinotecan, Trastuzumab, Panitumumab, Capecitabine, Calcium Levofolinate, Folinic Acid, Oxaliplatin, Fluorouracil, Pertuzumab, Ipilimumab, and Nivolumab. These medications are administered in various forms, such as injections, infusions, and oral capsules.

The purpose of the study is to determine if a personalized treatment strategy, guided by a blood test called ctDNA (circulating tumor DNA), can improve outcomes for patients compared to the standard chemotherapy approach. The study will involve randomizing patients into different treatment groups based on their ctDNA results after surgery. Some patients will receive conventional chemotherapy, while others will receive a personalized treatment plan. The study will also include a group receiving a placebo to compare the effectiveness of the treatments.

Participants in the trial will undergo treatment for a maximum period of six months. The study will monitor the patients’ health and response to the treatments over time, with follow-ups to assess the long-term effects. The trial aims to provide valuable insights into the potential benefits of personalized treatment strategies for colon cancer patients, ultimately aiming to improve their quality of life and survival rates.